To assess the incidence, prognostic factors, and clinical outcomes of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) creation.
Materials and Methods
In this single-institution retrospective study, 191 patients (m:f = 114:77, median age 54 years, median Model for End-Stage Liver Disease or MELD score 14) who underwent TIPS creation between 1999 and 2013 were studied. Medical record review was used to identify demographic characteristics, liver disease, procedure, and outcome data. Post-TIPS HE within 30 days was defined by new mental status changes and was graded according to the West Haven classification system. The influence of data parameters on HE occurrence and 90-day mortality was assessed using binary logistic regression.
TIPS was successfully created with hemodynamic success in 99 % of cases. Median final PSG was 7 mmHg. HE incidence within 30 days was 42 % (81/191; 22 % de novo, 12 % stable, and 8 % worsening). Degrees of HE included grade 1 (46 %), grade 2 (29 %), grade 3 (18 %), and grade 4 (7 %). Medical therapy typically addressed HE, and shunt reduction was necessary in only three cases. MELD score (P = 0.020) and age (P = 0.009) were significantly associated with HE development on multivariate analysis. Occurrence of de novo HE post-TIPS did not associate with 90-day mortality (P = 0.400), in contrast to worsening HE (P < 0.001).
The incidence of post-TIPS HE is non-trivial, but symptoms are typically mild and medically managed. HE rates are higher in older patients and those with worse liver function and should be contemplated when counseling on expected TIPS outcomes and post-procedure course.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014–2021.
Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol. 2012;18:6693–6700.
Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–1976.
Garcia-Pagan JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50.
Boyer TD, Haskal ZJ, American Association for the Study of Liver Disease. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.
Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–635.
Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013. doi:10.1155/2013/398172.
Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM. 2008;101:493–501.
Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–2746.
Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27:742–747.
Tripathi D, Ferguson J, Barkell H, et al. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. Eur J Gastroenterol Hepatol. 2006;18:225–232.
Mamiya Y, Kanazawa H, Kimura Y, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res. 2004;30:162–168.
Dissanayake O, MacNaughton J, Patch D, Morgan MY. Hepatic encephalopathy is a significant predictor of mortality following tips insertion for refractory ascites. J Hepatol. 2013;58:S420–S421.
Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for transjugular intrahepatic portosystemic shunt (TIPS). Cardiovasc Interv Radiol. 2012;35:1295–1300.
Qin JP, Jiang MD, Tang W, et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center. World J Gastroenterol. 2013;19:8085–8092.
Gaba RC, Omene BO, Podczerwinski ES, et al. TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol. 2012;23:227–235.
Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28:1215–1225.
Haskal ZJ, Rees CR, Ring EJ, Saxon R, Sacks D, Society of Interventional Radiology Technology Assessment Committee. Reporting standards for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2003;14:S419–S426.
Sze DY, Hwang GL, Kao JS, et al. Bidirectionally adjustable TIPS reduction by parallel stent and stent-graft deployment. J Vasc Interv Radiol. 2008;19:1653–1658.
Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16:301–320.
Hagan MT, Sayuk GS, Lisker-Melman M, et al. Liver volume in the cirrhotic patient: does size matter? Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3038-1.
Zhu JY, Leng XS, Dong N, Qi GY, Du RY. Measurement of liver volume and its clinical significance in cirrhotic portal hypertensive patients. World J Gastroenterol. 1999;5:525–526.
Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674–679.
Tong C, Xu X, Liu C, Zhang T, Qu K. Assessment of liver volume variation to evaluate liver function. Front Med. 2012;6:421–427.
May BJ, Talenfeld AD, Madoff DC. Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol. 2013;24:241–254.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Gastroenterology. 2001;120:A76–A77.
Gaba RC, Couture PM, Bui JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2013;24:411–420.
Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci. 2011;56:977–987.
Conflict of interest
About this article
Cite this article
Casadaban, L.C., Parvinian, A., Minocha, J. et al. Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes. Dig Dis Sci 60, 1059–1066 (2015). https://doi.org/10.1007/s10620-014-3391-0
- Hepatic encephalopathy (HE)
- Transjugular intrahepatic portosystemic shunt (TIPS)
- Prognostic factors
- Clinical outcomes